Severe frequent ventricular ectopy after exercise as a predictor of death in patients with heart failure  by O'Neill, James O. et al.
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OBJECTIVES The study was done to determine the prognostic importance of frequent ventricular ectopy in
recovery after exercise among patients with systolic heart failure (HF).
BACKGROUND Although ventricular ectopy during recovery after exercise predicts death in patients
without HF, its prognostic importance in patients with significant ventricular dysfunction
is unknown.
METHODS Systematic electrocardiographic data during rest, exercise, and recovery were gathered on
2,123 consecutive patients with left ventricular systolic ejection fraction 35% who were
referred for symptom-limited metabolic treadmill exercise testing. Severe ventricular ectopy
was defined as the presence of ventricular triplets, sustained or nonsustained ventricular
tachycardia, ventricular flutter, polymorphic ventricular tachycardia, or ventricular fibrillation.
The primary end point was all-cause mortality, with censoring for interval cardiac transplan-
tation.
RESULTS Of 2,123 patients, 140 (7%) had severe ventricular ectopy during recovery. There were 530
deaths (median follow-up among survivors 2.9 years). Severe ventricular ectopy during
recovery was associated with an increased risk of death (three-year death rates 37% vs. 22%,
hazard ratio [HR] 1.76; 95% confidence interval [CI] 1.32 to 2.34, p  0.0001). After
adjustment for ventricular ectopy at rest and during exercise, peak oxygen uptake, and other
potential confounders, severe ventricular ectopy during recovery remained predictive of death
(adjusted HR 1.48; 95% CI 1.10 to 1.97; p  0.0089), whereas ventricular ectopy during
exercise was not predictive of death in this cohort.
CONCLUSIONS Severe ventricular ectopy during recovery after exercise is predictive of increased mortality in
patients with severe HF and can be used as a prognostic indicator of adverse outcomes in HF
cohorts. (J Am Coll Cardiol 2004;44:820–6) © 2004 by the American College of
Cardiology Foundatione
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lentricular ectopy at rest is common in patients with
epressed left ventricular (LV) systolic function, and sudden
eath is responsible for 30% to 50% of mortality in heart
ailure (HF) patients (1). Among patients without HF,
requent ventricular ectopy during and/or after exercise has
een shown to predict a higher death risk (2,3). The
rognostic importance of ventricular ectopy during or after
xercise among patients with advanced HF is unclear.
See page 827
As autonomic abnormalities that predispose to ventricu-
ar arrhythmias are common in severe HF (4), we hypoth-
sized that ventricular ectopy during or after exercise would
lso be predictive of increased risk in this setting. Further-
ore, as recovery immediately after exercise is thought to be
time when vagal reactivation should be rapidly occurring,
e hypothesized that ventricular ectopy during recovery
ould be more predictive.
From the *Department of Cardiovascular Medicine, Cleveland Clinic Foundation,
leveland, Ohio. Dr. Lauer and Ms. Pothier receive support from the National Heart,
ung, and Blood Institute (Grant HL-66004); Dr. O’Neill receives support from the
ulbright Commission.
Manuscript received December 11, 2003; revised manuscript received February 11,N004, accepted February 24, 2004.In this study, we analyzed the prognostic value of
xercise-related ventricular ectopy in patients with HF
eferred for metabolic gas exchange exercise testing.
ETHODS
atients. Consecutive Cleveland Clinic Foundation pa-
ients with LV systolic ejection fraction 35% who were
eferred for metabolic treadmill exercise testing between
anuary 1995 and December 2002 were considered for
nclusion. Patients were excluded for the following rea-
ons: age 20 years, absence of U.S. social security
umber, congenital or primary valvular heart disease,
nd-stage renal disease, or history of cardiac transplan-
ation. In patients with more than one metabolic exercise
est, only the initial study was included in the analysis.
ata were prospectively recorded on a customized com-
uter database, which was approved by the Institutional
eview Board of the Cleveland Clinic Foundation. The
equirement for obtaining informed consent was waived.
linical and exercise data. Before each metabolic stress
est, a structured interview and chart review yielded pro-
pectively obtained data on demographics, LV ejection
raction, medications, etiology of HF, and various other
linical parameters as defined previously (5). Symptom-
imited metabolic stress testing was performed using theaughton protocol and recorded on a MedGraphics car-
d
d
b
(
m
w
d
e
l
e
V
l
a
n
t
t
w
k
c
t
r
V
fi
e
a
v
m
c
f
p
i
L
d
n
p
t
v
v
E
i
S
t
i
(
t
t
t
t
S
w
e
i
T
F
e
821JACC Vol. 44, No. 4, 2004 O’Neill et al.
August 18, 2004:820–6 Exercise Ventricular Ectopy and HFiopulmonary system. Data were prospectively collected
uring each stage of exercise on symptoms, rhythm, and
lood pressure. Measurements of oxygen consumption
VO2), carbon dioxide production (VCO2), heart rate,
inute ventilation (VE), tidal volume, and respiratory rate
ere made after steady state at rest and after every 30 s
uring exercise and recovery. The ventilatory response to
xercise was defined as the value of ratio of minute venti-
ation to carbon dioxide production (VE/VCO2) at peak
xercise (5). Anaerobic threshold was determined by the
-slope method (6) or by inspection of ventilatory equiva-
ents (7).
Because of the inclusion of patients with atrial fibrillation
nd patients actively receiving beta-blocker therapy, chro-
otropic response (previously documented to have prognos-
ic significance in exercise testing [8]) was not included in
he analyses. In addition, because of the inclusion of patients
ith permanent pacemakers, heart rate recovery (also
nown to be of prognostic importance [9]) was also not
onsidered. The Duke treadmill score was not included for
he above reasons and because of the prevalence of abnormal
esting electrocardiograms in this population.
igure 1. Kaplan-Meier analysis of survival according to the absence or p
Abbreviations and Acronyms
CI  confidence interval
HF  heart failure
HR  hazard ratio
LV  left ventricular
VCO2  carbon dioxide production (in ml/kg/min)
VE  minute ventilation
VE/VCO2  ratio of minute ventilation to carbon dioxide
production
VO2  oxygen consumption (in ml/kg/min)ctopy during recovery after exercise. VEA  ventricular ectopic activity.entricular ectopy. Ventricular ectopy was previously de-
ned (10). Briefly, systematic data were gathered on the
lectrocardiogram and during rest, exercise, and recovery
nd analyzed according to prespecified definitions. Frequent
entricular ectopy was defined as the presence of seven or
ore ventricular premature beats/min, frequent ventricular
ouplets, ventricular bigeminy or trigeminy, or any other
orm of ventricular tachycardia (either monomorphic or
olymorphic) or ventricular fibrillation.
Patients with frequent ventricular ectopy were subdivided
nto less severe and more severe categories based on the
own classification (11). Severe ventricular ectopy was
efined as the presence of ventricular triplets, sustained or
onsustained ventricular tachycardia, ventricular flutter,
olymorphic ventricular tachycardia, or ventricular fibrilla-
ion. Sustained ventricular arrhythmias were defined as
entricular flutter, polymorphic ventricular tachycardia, or
entricular fibrillation.
nd points. The primary end point was all-cause mortal-
ty, which was determined with reference to the Social
ecurity Death Index (12,13). We have previously shown
hat this method has a sensitivity of 97% for detecting death
n Cleveland Clinic Foundation exercise laboratory patients
8). Cross-referencing our unified transplant database iden-
ified patients later undergoing orthotopic heart transplan-
ation. Patients who underwent cardiac transplant during
he period of the study were censored at the time of
ransplantation.
tatistical analyses. For descriptive purposes, patients
ere divided into three groups: (1) no frequent ventricular
ctopy in recovery, (2) nonsevere frequent ventricular ectopy
n recovery, and (3) severe ventricular ectopy in recovery.
he Kruskal-Wallis test was used for comparisons of
ce of nonsevere frequent ventricular ectopy or severe frequent ventricularresen
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Exercise Ventricular Ectopy and HF August 18, 2004:820–6ontinuous variables, whereas the chi-square test for trend
as used to test for comparisons of categorical variables.
Kaplan-Meier curves were constructed (Fig. 1) and Cox
tepwise selection proportional hazards modeling was per-
ormed to analyze the association of recovery ventricular
ctopy and death. The proportional hazards assumption was
onfirmed by testing an interaction with follow-up time as
able 1. Clinical and Cardiovascular Characteristics of the Study
ctopy During Recovery After Exercise
Variable
No Frequen
Ventricular Ect
(n  1,833)
emographic characteristics
Age (yrs) 54  11
Male gender, no. (%) 1,354 (74)
Black, no. (%) 199 (11)
linical history, no. (%)
Diabetes, insulin-treated 161 (9)
Diabetes, non–insulin-treated 306 (17)
Hypertension 898 (49)
Tobacco use 399 (22)
Known coronary artery disease 928 (51)
Prior myocardial infarction 709 (39)
Prior coronary artery bypass grafting 468 (26)
Prior percutaneous coronary intervention 342 (19)
Pacemaker 346 (19)
Implantable defibrillator 350 (19)
Atrial fibrillation 99 (5)
Peripheral vascular disease 79 (4)
Carotid artery disease 101 (6)
COPD 161 (9)
Asthma 124 (7)
Prior stroke 87 (5)
Prior TIA 80 (4)
edication use, no. (%)
Beta-blocker 800 (44)
ACE inhibitor 1,511 (82)
Angiotensin receptor blocker 155 (8)
Amiodarone 395 (22)
Sotalol 14 (1)
Calcium channel blocker 27 (1)
Aspirin 749 (41)
Statin 530 (29)
Spirinolactone 360 (20)
Digoxin 1,442 (79)
Loop diuretic 1,534 (84)
Thiazide diuretic 219 (12)
ardiovascular assessment
Body mass index 28  6
Resting heart rate (beats/min) 79  15
Resting blood pressure (mm Hg)
Systolic 109  18
Diastolic 74  11
Left ventricular ejection fraction (%) 20  7
Peak oxygen consumption (ml/kg/min) 16.5  5.2
VE/VCO2 33.3  9.7
Nonsevere ventricular ectopy (rest), no. (%) 14 (1)
Severe ventricular ectopy (rest), no. (%) 12 (1)
Severe ventricular ectopy (exercise), no. (%) 34 (2)
Nonsevere ventricular ectopy (exercise), no. (%) 67 (4)
CE  angiotensin-converting enzyme; COPD  chronic obstructive pulmonary di
entilation.time-dependent covariate. Three proportional hazardsodels were generated. The simplest model considered only
evere and nonsevere frequent ventricular ectopy in recovery.
he next model considered severe and nonsevere frequent
entricular ectopy in recovery, in exercise, and at rest.
inally, we added to all six of the ventricular ectopy variables
number of potential confounders including all the vari-
bles listed in Table 1.
ents According to the Absence or Presence of Ventricular
Frequent Non-Severe
Ventricular Ectopy
(n  150)
Frequent Severe
Ventricular Ectopy
(n  140) p Value
54  12 57  10 0.0008
117 (78) 122 (87) 0.0004
15 (10) 17 (12) 0.78
11 (7) 5 (4) 0.03
16 (11) 16 (11) 0.03
67 (45) 69 (49) 0.73
34 (25) 33 (24) 0.86
81 (54) 70 (50) 0.84
51 (34) 51 (36) 0.35
41 (27) 41 (29) 0.29
24 (16) 21 (15) 0.20
21 (14) 21 (15) 0.11
39 (26) 34 (24) 0.03
7 (5) 18 (13) 0.002
5 (3) 6 (4) 0.84
8 (5) 10 (7) 0.50
15 (10) 21 (15) 0.02
8 (5) 7 (5) 0.32
11 (7) 3 (2) 0.52
5 (3) 5 (4) 0.52
74 (49) 53 (38) 0.53
118 (79) 118 (84) 0.99
15 (10) 14 (10) 0.41
22 (15) 20 (14) 0.009
2 (1) 2 (1) 0.62
2 (1) 2 (1) 0.93
66 (44) 54 (30) 0.87
46 (31) 39 (29) 0.96
19 (13) 23 (16) 0.09
113 (75) 118 (84) 0.32
121 (81) 125 (89) 0.25
21 (14) 22 (16) 0.15
28  5 28  5 0.73
74  15 79  15 0.003
110  17 108  17 0.44
73  11 72  11 0.18
20  6 19  7 0.42
18.0  5.7 16.5  4.3 0.007
31.9  8.8 34.3  9.5 0.22
37 (25) 22 (16) 0.0001
2 (1) 18 (13) 0.0001
20 (13) 51 (36) 0.0001
63 (42) 28 (20) 0.0001
IA  transient ischemic attack; VCO2  carbon dioxide production; VE  minutePati
t
opy
sease; TWe tested for possible interactions by means of prespeci-
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August 18, 2004:820–6 Exercise Ventricular Ectopy and HFed subset analyses and interaction terms. Specifically, we
tratified patients according to age, gender, prior implant-
ble defibrillator placement, peak VO2, ventilatory response
o exercise, body mass index, use of medications (including
spirin, beta-blockers, and metolazone), known carotid
isease, and known chronic lung disease. All analyses were
erformed with SAS software (version 8.2, SAS Institute,
ary, North Carolina).
ESULTS
here were 2,123 patients eligible for analysis. Of this
ohort, 290 patients (14%) had frequent ventricular ectopy
n recovery, of whom 140 (48%) had severe ventricular
ctopy in recovery. Five patients (0.2%) developed sustained
entricular arrhythmias during recovery after exercise.
Clinical and metabolic exercise data according to pres-
nce or absence of ventricular ectopy in recovery are shown
n Table 1. Patients with frequent ventricular ectopy during
ecovery were older and more likely to be male, to have a
istory of atrial fibrillation or chronic obstructive pulmonary
isease, and were less likely to be taking amiodarone. The
resence of severe ventricular ectopy at rest was correlated
ith severe ventricular ectopy during recovery.
There were 530 deaths during a median follow-up of 2.9
ears (25th and 75th percentiles, 1.4 and 4.9 years, respec-
ively); during that time, 198 (9%) underwent cardiac
ransplantation. Among patients with severe ventricular
ctopy in recovery, there were 51 deaths, and among those
ith nonsevere frequent ventricular ectopy in recovery, there
ere 34 deaths. Severe frequent ectopy in recovery predicted
higher mortality (hazard ratio [HR] 1.76; 95% confidence
nterval [CI] 1.32 to 2.34; p  0.0001) compared to no
requent ventricular ectopy or nonsevere frequent ventricular
ctopy during recovery after exercise (Fig. 1).
In a model that included severe ventricular ectopy in
ecovery, nonsevere ventricular ectopy in recovery, severe
entricular ectopy during exercise, nonsevere ventricular
ctopy during exercise, severe ventricular ectopy at rest, and
onsevere ventricular ectopy at rest, the only variable pre-
ictive of mortality was severe ventricular ectopy during
ecovery (adjusted HR 1.55; 95% CI 1.12 to 2.15; p 
.009).
Using a subsequent multivariable Cox regression model,
fter adjustment for baseline clinical and cardiovascular
ariables, severe frequent ventricular ectopy in recovery
emained predictive of death (adjusted HR 1.48; 95% CI
.10 to 1.97; p  0.0089). The strongest predictor overall
as peak VO2. Other independent predictors included male
ender, concomitant thiazide diuretic use, lower resting
iastolic blood pressure, carotid artery disease, chronic
bstructive lung disease, and lower body mass index. Beta-
locker and aspirin therapy were protective (Table 2).
In addition to stepwise modeling, a multivariate model
as created that forced in age, chronic obstructive lung
isease, amiodarone, and atrial fibrillation, in addition to ahe six ventricular ectopy variables (nonsevere and severe,
uring rest, exercise, and recovery). The only ventricular
ctopy variable that was a significant predictor of death was
evere ventricular ectopy during recovery (adjusted HR 1.43;
5% CI 1.03 to 1.99; p  0.035). Other variables in this
onstepwise model that were significant predictors of death
ere age (adjusted HR 1.03; 95% CI 1.02 to 1.04; p 
.0001), chronic obstructive pulmonary disease (adjusted
R 1.52; 95% CI 1.18 to 1.96; p  0.0011), and amioda-
one therapy (adjusted HR 1.45; 95% CI 1.19 to 1.77; p 
.0002).
The results of prespecified subgroup analyses are shown
n Table 3 Severe ventricular ectopy in recovery was asso-
iated with higher death rates in nearly all subgroups. Of
ote, a borderline interaction was noted whereby severe
entricular ectopy in recovery was a stronger predictor of
isk among patients with an VO2 of 14 ml/kg/min.
ISCUSSION
n a large cohort of patients with severe LV dysfunction and
F, the presence of severe ventricular ectopy during recov-
ry was independently predictive of risk of death even after
ccounting for maximum VO2, ejection fraction, ventricular
ctopy at rest or during exercise, and other potential
onfounders. Our findings in this group of very ill patients
arallel our previous report of the prognostic power of
entricular ectopy during recovery after exercise among a
ery large cohort of patients without HF (2).
Despite advances in therapy, HF continues to carry a
9% five-year age-adjusted mortality (14). Cardiac trans-
lantation has a median survival of 10 years (15). Organ
able 2. Predictors of Mortality by Multivariable Analysis:
ariables Are Shown in the Order They Entered a Stepwise
ox Regression Model
Variable*
Adjusted Hazard
Ratio (95% CI)
p
Value
eak oxygen consumption
(decrease of 5 ml/kg/min)
2.07 (1.85–2.31) 0.0001
ale gender 2.00 (1.56–2.55) 0.0001
eta-blocker therapy 0.64 (0.52–0.77) 0.0001
hiazide diuretic 1.69 (1.36–2.10) 0.0001
esting diastolic blood pressure 0.98 (0.98–0.99) 0.0001
arotid artery disease 1.64 (1.21–2.20) 0.0013
evere ventricular ectopy in recovery 1.48 (1.10–1.97) 0.0089
spirin therapy 0.79 (0.66–0.95) 0.013
hronic obstructive lung disease 1.39 (1.08–1.79) 0.011
ody mass index (decrease of 5 kg/m2) 1.12 (1.04–1.22) 0.005
mplantable defibrillator 0.78 (0.619–0.98) 0.038
Only variables with p  0.05 are shown. The following variables were rejected from
he model, using a criterion of p  0.05 for model entry and retention: age, race,
esting pulse rate, resting systolic blood pressure, ejection fraction, history of atrial
brillation, ischemic heart disease, diabetes, hypertension, smoking history, family
istory, prior myocardial infarction, prior coronary artery bypass grafting, prior
ercutaneous intervention, pacemaker, peripheral vascular disease, asthma, prior
troke, prior transient ischemic attack, VE/VCO2, angiotensin-converting enzyme
nhibitor, digoxin, angiotensin-II antagonists, loop diuretics, spironolactone, nitrates,
tatins, fibrates, inhaled beta-2 agonists, amiodarone, and sotalol.
CI  confidence interval.vailability limits the number of transplants to approxi-
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Exercise Ventricular Ectopy and HF August 18, 2004:820–6ately 2,000 per year in the U.S., well below require-
ents and only a small fraction of the 5 million or so
mericans with HF. Identifying patients at high risk of
eath is vital to appropriately select patients for referral
or advanced therapies including heart transplantation.
onventional predictors of mortality include gender, LV
nd right ventricular ejection fractions, functional class,
schemic etiology, the presence of significant co-
orbidities, and peak oxygen uptake levels determined
n metabolic exercise testing (16).
Weber et al. (17) first described the use of peak VO2 in
mbulatory patients with HF as a means of formally
ssessing functional status. Exercise data from the first
eterans Administration Heart Failure Trial demonstrated
hat peak VO2 independently predicted mortality (18). A
tudy of 116 patients being considered for cardiac transplan-
ation in the University of Pennsylvania program found that
n patients with a peak VO2 of14 ml/kg/min, the freedom
rom death or urgent cardiac transplantation was only 48%
t one year (19). Patients without significant co-morbidities
nd with a peak VO2 of 14 ml/kg/min had a one-year
able 3. Association Between Severe Ventricular Ectopy During
Stratifying Variable
No Severe Ventricular
Ectopy During Recovery
Deaths/No. of Patients (%)
ge
60 yrs 270/1,343 (20)
60 yrs 209/640 (33)
mplantable defibrillator
Yes 77/389 (20)
No 402/1,594 (25)
ender
Male 391/1,471 (27)
Female 88/512 (17)
tiology of heart failure
Ischemic 279/1,009 (28)
Nonischemic 200/974 (21)
eak oxygen consumption
14 ml/kg/min 244/676 (36)
14 ml/kg/min 235/1,307 (18)
E/VCO2
35 238/747 (32)
35 241/1,236 (20)
ody mass index
25 161/617 (26)
25 318/1,366 (23)
spirin therapy
Yes 173/815 (21)
No 306/1,168 (26)
eta-blocker therapy
Yes 124/874 (14)
No 355/1,109 (32)
OPD
Yes 64/176 (36)
No 415/1,807 (23)
evere ventricular ectopy with exercise
Yes 15/54 (28)
No 464/1,929 (24)
bbreviations as in Tables 1 and 2.urvival of 94%. A consensus exists that an ejection fraction20% and a peak VO2 of14 ml/kg/min should be present
o warrant referral for cardiac transplantation (20). Some
rgue that there is an overreliance placed on this single end
oint for prognosis (21). Ventilatory and heart rate re-
ponses to exercise may be superior to peak VO2 as predic-
ors of mortality (5). The current report suggests that in a
mall number of patients the presence of severe ventricular
ctopy during recovery may be an additional useful predictor
f high risk.
Patients with HF have autonomic impairment at rest,
anifested by reduced heart rate variability (22) and im-
aired baro-receptor responsiveness (4), both of which
redict increased mortality in these patients. In addition,
ome HF patients have been shown to have blunted heart
ate responses to exercise (23) and abnormal hyperventila-
ion (24) as prognostically important manifestations of
utonomic dysfunction. The presence of severe ventricular
ctopy during recovery, a time when vagal reactivation
ught to be occurring, may be a marker of a greater severity
f autonomic disturbance and hence correlate with a greater
isk of death.
very and Mortality in Prespecified Subgroups
Severe Ventricular Ectopy
During Recovery
Deaths/No. of Patients (%)
Relative Risk
(95% CI)
p Value for
Interaction
22/77 (29) 1.51 (0.98–2.33) 0.53
29/63 (46) 1.83 (1.24–2.71)
11/34 (32) 1.91 (1.01–3.60) 0.90
40/106 (38) 1.75 (1.26–2.42)
44/122 (36) 1.56 (1.15–2.14) 0.29
7/18 (39) 2.46 (1.14–5.30)
25/70 (36) 1.63 (1.08–2.46) 0.52
26/70 (37) 1.99 (1.32–2.99)
20/42 (48) 1.26 (0.80–1.99) 0.05
31/98 (32) 2.28 (1.57–3.32)
29/57 (51) 1.73 (1.18–2.55) 0.81
22/83 (27) 1.64 (1.06–2.54)
16/40 (40) 1.93 (1.15–3.23) 0.68
35/100 (35) 1.70 (1.20–2.41)
18/54 (33) 1.74 (1.07–2.83) 0.94
33/86 (38) 1.76 (1.23–2.53)
12/53 (23) 1.81 (1.00–3.28) 0.84
39/87 (45) 1.68 (1.21–2.34)
9/21 (43) 1.49 (0.74–3.01) 0.69
42/119 (35) 1.75 (1.27–2.40)
22/51 (43) 2.25 (1.16–4.36) 0.29
29/89 (33) 1.45 (1.00–2.11)RecoSome important limitations of our study require mention.
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August 18, 2004:820–6 Exercise Ventricular Ectopy and HFur data are derived from a cohort seen at a referral center
ith a high cardiac transplant volume; hence, there will be
need to confirm our results elsewhere. Use of the Social
ecurity Death Index meant that we did not have data
egarding the mechanism of death in these patients. Others
nd we have addressed in detail the issue of assessing cause
f death in patients with cardiovascular disease and HF.
rguments have been made that attempting to classify cause
f death may be problematic, whereas all-cause mortality is
n objective, clinically relevant, and unbiased end point
25–27).
Resting ventricular ectopy was based only on a short
re-exercise recording, rather than a prolonged ambulatory
onitor. We could not incorporate chronotropic response
r heart rate recovery into our survival models because of the
nclusion of patients with atrial fibrillation, pacemakers, and
eta-blocker use. Indeed, beta-blocker use was only in the
egion of 44% of patients, reflecting the era of the data
January 1995 to December 2002). Contemporary practice
ow incorporates significantly higher use of beta-blocking
herapy. This may limit somewhat the extrapolation of this
ata to the current heart failure cohort. In addition, we
ould not allow for the potential effects of interventions
erformed following the exercise stress test in patients who
eveloped arrhythmias, which may have included changes in
edications, a search for myocardial ischemia, or the
mplantation of cardioverter-defibrillators, which may have
ltered outcomes. Of note, though, only five patients devel-
ped sustained ventricular arrhythmias during recovery,
uggesting that this is unlikely.
Cardiac transplantation was a competing event, which we
reated by censoring; this seems a reasonable strategy as it is
nlikely that patients were specifically chosen for transplant
ecause of ventricular ectopy after exercise, which was not
ppreciated as a predictor of risk at the time these patients
ere exercised. Finally, even though it was an independent
redictor of death, severe ventricular ectopy during recovery
as a relatively uncommon finding.
Despite these limitations, our findings lend further cre-
ence to the potential clinical value of ventricular ectopy
uring recovery after exercise. In this cohort of HF patients,
his finding was independently predictive of death, partic-
larly among patients with an VO2 14 ml/kg/min, and
ence may be useful for identifying previously unrecognized
andidates for aggressive HF therapies. Future research will
e needed to confirm these findings and to determine how
est to incorporate the finding of recovery ventricular ectopy
nto exercise test interpretation among patients with and
ithout HF.
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oundation, Desk F25, 9500 Euclid Ave., Cleveland, OH
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